120 related articles for article (PubMed ID: 8696533)
1. Prevention of restenosis by bezafibrate after successful coronary angioplasty.
Ishiwata S; Nakanishi S; Nishiyama S; Seki A
Coron Artery Dis; 1995 Nov; 6(11):883-9. PubMed ID: 8696533
[TBL] [Abstract][Full Text] [Related]
2. [The importance of serum lipid level for restenosis following initial successful percutaneous transluminal coronary angioplasty in patients with unstable angina].
Kishi K; Hiasa Y; Tanaka H; Tanimoto M; Kinoshita M; Shinohara A; Wada T; Aihara T
J Cardiol; 1996 Aug; 28(2):79-84. PubMed ID: 8814525
[TBL] [Abstract][Full Text] [Related]
3. [Preventive effect of pravastatin on restenosis following coronary angioplasty: prospective randomized trial].
Iwasaki K; Kusachi S; Hina K; Yamasaki S; Nishiyama O; Takaishi A; Kita T; Taniguchi G
J Cardiol; 1995 Jan; 25(1):15-21. PubMed ID: 7877098
[TBL] [Abstract][Full Text] [Related]
4. A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis.
Huber K; Jörg M; Probst P; Schuster E; Lang I; Kaindl F; Binder BR
Thromb Haemost; 1992 Feb; 67(2):209-13. PubMed ID: 1621240
[TBL] [Abstract][Full Text] [Related]
5. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
[TBL] [Abstract][Full Text] [Related]
6. High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study.
Arcavi L; Behar S; Caspi A; Reshef N; Boyko V; Knobler H
Am Heart J; 2004 Feb; 147(2):239-45. PubMed ID: 14760320
[TBL] [Abstract][Full Text] [Related]
7. [Different effects of inflammation and lipid levels on coronary lesions after PCI].
Xu HY; Qiao SB; Li JJ; Yang YJ; Zhang JF; Xu B; Xie GQ; Dong QT
Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(32):2249-52. PubMed ID: 20095335
[TBL] [Abstract][Full Text] [Related]
8. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial.
Goldenberg I; Boyko V; Tennenbaum A; Tanne D; Behar S; Guetta V
Arch Intern Med; 2009 Mar; 169(5):508-14. PubMed ID: 19273782
[TBL] [Abstract][Full Text] [Related]
9. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R
Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
[TBL] [Abstract][Full Text] [Related]
10. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque.
Kowalski M
J Physiol Pharmacol; 2001 Aug; 52(1 Suppl 1):3-31. PubMed ID: 11795863
[TBL] [Abstract][Full Text] [Related]
11. Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort.
Clearfield MB; Weis SE; Willis JM; Vasenius KA; McConathy WJ
J Am Osteopath Assoc; 2002 Jul; 102(7):377-84. PubMed ID: 12138952
[TBL] [Abstract][Full Text] [Related]
12. Impaired fibrinolytic capacity and tissue plasminogen activator release in patients with restenosis after percutaneous transluminal coronary angioplasty (PTCA).
Kirschstein W; Simianer S; Dempfle CE; Keller H; Stegaru B; Rentrop P; Heene DL
Thromb Haemost; 1989 Sep; 62(2):772-5. PubMed ID: 2510351
[TBL] [Abstract][Full Text] [Related]
13. Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial).
Goldenberg I; Goldbourt U; Boyko V; Behar S; Reicher-Reiss H;
Am J Cardiol; 2006 Feb; 97(4):466-71. PubMed ID: 16461038
[TBL] [Abstract][Full Text] [Related]
14. Association of antibodies to heat-shock protein-65 with percutaneous transluminal coronary angioplasty and subsequent restenosis.
Mukherjee M; De Benedictis C; Jewitt D; Kakkar VV
Thromb Haemost; 1996 Feb; 75(2):258-60. PubMed ID: 8815572
[TBL] [Abstract][Full Text] [Related]
15. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
16. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study.
Goldbourt U; Brunner D; Behar S; Reicher-Reiss H
Eur Heart J; 1998 Jul; 19 Suppl H():H42-7. PubMed ID: 9717065
[TBL] [Abstract][Full Text] [Related]
17. Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress.
Ericsson CG
Eur Heart J; 1998 Jul; 19 Suppl H():H37-41. PubMed ID: 9717064
[TBL] [Abstract][Full Text] [Related]
18. A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease.
Goel PK; Bharti BB; Pandey CM; Singh U; Tewari S; Kapoor A; Garg N; Sinha N
Indian Heart J; 2003; 55(3):234-40. PubMed ID: 14560932
[TBL] [Abstract][Full Text] [Related]
19. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
Li JZ; Chen ML; Wang S; Dong J; Zeng P; Hou LW
Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
[TBL] [Abstract][Full Text] [Related]
20. Restenosis after percutaneous transluminal coronary angioplasty in patients with non-insulin-dependent diabetes mellitus (NIDDM).
Asakura Y; Suzuki M; Nonogi H; Haze K; Sato A; Inada H; Okuda Y; Yamashita K; Harano Y
J Cardiovasc Risk; 1998; 5(5-6):331-4. PubMed ID: 9920005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
